Associated tags: AAV, Gene editing, Disease, PNH, Patient, PKU, Hunter syndrome, Phenylketonuria, Paroxysmal nocturnal hemoglobinuria, Antibody, MLD, Therapy, Pharmaceutical industry, Vaccine, Safety, Failure, COVID-19, JumpStart
Locations: MASSACHUSETTS, BEDFORD, MA, US
BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming investor conferences.
Key Points:
- BEDFORD, Mass., Sept. 03, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in two upcoming investor conferences.
- Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.
- Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs.
- Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
Key Points:
- -
BEDFORD, Mass., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the quarter ended June 30, 2019, and highlighted recent accomplishments.
- This capability is an important strategic advantage for Homology as we progress our lead program in PKU in the clinic and advance our pipeline.
- Therefore, we strengthened our balance sheet in the second quarter by raising $144 million from existing investors and attracting support from new, top-tier funds.
- Research and development expenses for the quarter ended June 30, 2019 were $22.8 million, compared to $10.3 million for the same period in 2018.
BEDFORD, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, at 11:30 a.m.
Key Points:
- BEDFORD, Mass., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a fireside chat at the Canaccord Genuity 39th Annual Growth Conference on Wednesday, August 7, at 11:30 a.m.
- In addition, Arthur Tzianabos, Ph.D., President and Chief Executive Officer of Homology Medicines, will participate in a panel on gene therapy at the BTIG Biotechnology Conference on Monday, August 12, at 3:00 p.m.
- Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.
- Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
BEDFORD, Mass., Oct. 1, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Homology will present at the following conferences:
Key Points:
- BEDFORD, Mass., Oct. 1, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Homology will present at the following conferences:
2018 Cell & Gene Meeting on the Mesa on October 3, 2018 at 2:15 p.m. PT at the Estancia La Jolla Hotel & Spa in California
Chardan Genetic Medicines Conference on October 9, 2018 at 8:00 a.m.
- Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.
- Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases, and intellectual property covering its suite of 15 AAVHSCs.
- Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
BEDFORD, Mass., Aug. 30, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a panel on gene editing during Citi's 13th Annual Biotech Conference at 1:15 p.m.
Key Points:
- BEDFORD, Mass., Aug. 30, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a panel on gene editing during Citi's 13th Annual Biotech Conference at 1:15 p.m.
- ET on Wednesday, September 5th at the Four Seasons in Boston.
- Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.
- Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
BEDFORD, Mass., Aug. 13, 2018 /PRNewswire/ --Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the quarter ended June 30, 2018, and highlighted recent accomplishments.
Key Points:
- BEDFORD, Mass., Aug. 13, 2018 /PRNewswire/ --Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the quarter ended June 30, 2018, and highlighted recent accomplishments.
- All other therapeutic approaches that do not replace the mutated gene, including those delivering a non-natural enzyme, require chronic dosing.
- Collaboration revenue for the quarter ended June 30, 2018 was $0.9 million in connection with a strategic collaboration with Novartis.
- Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.
BEDFORD, Mass., July 16, 2018 /PRNewswire/ --Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating that Homology's technology induces efficient and precise in vivo gene editing.
Key Points:
- BEDFORD, Mass., July 16, 2018 /PRNewswire/ --Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating that Homology's technology induces efficient and precise in vivo gene editing.
- "We continue to expect to nominate a gene editing development candidate this year and begin a clinical trial of our PKU gene therapy program next year."
- The editing vector contained a promoterless luciferase cDNA flanked by homology arms specific to the murine locus.
- In comparison, the editing vector without homology arms showed no luciferase expression, and a non-Clade F AAV8 editing vector showed limited expression.
BEDFORD, Mass., May 18, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of data from its gene therapy and gene editing programs at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
Key Points:
- BEDFORD, Mass., May 18, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today the presentation of data from its gene therapy and gene editing programs at the 21st Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT).
- New data presented from Homology's HMI-102 program, a gene therapy for phenylketonuria (PKU) in IND-enabling studies, demonstrate its potential as a one-time treatment designed to restore the normal metabolic pathway in PKU.
- The Company expects to initiate a Phase 1/2 clinical trial with HMI-102 in adult PKU patients and have initial datain 2019.
- "Our PKU programs are a great example of how we can use our technology platform to develop potential cures using a gene therapy approach for the adult population and gene editing for the pediatric population.
Biology,
Genetics,
Rare diseases,
Medicine,
Medical genetics,
Applied genetics,
Intellectual disability,
Phenylketonuria,
RTT,
Gene therapy,
Genetic disorder Homology will present new data with HMI-102, the Company's gene therapy product candidate in IND-enabling studies for the treatment of PKU.
Key Points:
- Homology will present new data with HMI-102, the Company's gene therapy product candidate in IND-enabling studies for the treatment of PKU.
- "We are focused on translating our technology into therapies that could substantially improve the lives of patients with PKU and other rare genetic diseases," said Albert Seymour, Ph.D., Chief Scientific Officer of Homology Medicines.
- "Our presentations at ASGCT demonstrate the potential of our human-derived AAVHSC vectors to address disease at the genetic level by using gene therapy or gene editing depending on the underlying biology of the disorder."
- Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease.
